Citizens JMP raised the firm’s price target on Neuronetics (STIM) to $7 from $3 and keeps an Outperform rating on the shares. Neuronetics’ Top-line quarterly results came in moderately ahead of the company’s mid-January preliminary announcement, and full-year 2025 guidance was maintained, the analyst tells investors in a research note. The stock’s nearly 20% increase on Tuesday was most likely from additional commentary on what has been driving the stock higher year to date — the potential growth, scale, and patient reach that the combined entity could achieve as a vertically integrated mental healthcare provider following the merger with Greenbrook TMS, the firm says.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STIM:
- 3 Best Stocks to Buy Now, 3/5/2025, According to Top Analysts
- Neuronetics’ Strategic Merger with Greenbrook TMS Fuels Growth and Positive Outlook
- Neuronetics Reports Growth Amid Strategic Acquisitions
- Target reports Q4 beat, Walgreens reportedly near go-private deal: Morning Buzz
- Neuronetics Reports Q4 2024 Results and Strategic Moves
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue